A
COLL icon

AJOVista’s Collegium Pharmaceutical COLL Stock Holding History

AJOVista’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-341
Closed -$10.5K – 157
2023
Q4 		$10.5K Buy
+341
New +$8.54K 0.01% 405

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AJOVista's COLL Position: Q1 2024 in Review

AJOVista sold out of Collegium Pharmaceutical (COLL) in Q1 2024, closing a stake of 341 shares — an estimated $10.5K sold.

AJOVista first reported a position in COLL in Q4 2023 and held it in 1 quarter. The position peaked at $10.5K in Q4 2023. 228 funds tracked by Wall St. Rank hold COLL as of Q1 2024.

  • AJOVista reported no remaining Collegium Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • AJOVista sold 341 Collegium Pharmaceutical shares in Q1 2024, an estimated $10.5K.
  • AJOVista first reported a position in Collegium Pharmaceutical in Q4 2023 and held it in 1 quarter.
  • AJOVista's Collegium Pharmaceutical position peaked at $10.5K in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.